BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 20192114)

  • 1. Interstitial infusion of erlotinib in the rodent brain.
    Luther N; Karampelas I; Souliopoulos EP; Edgar MA; Boockvar JA; Souweidane MM
    J Exp Ther Oncol; 2009; 8(2):79-84. PubMed ID: 20192114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraparenchymal and intratumoral interstitial infusion of anti-glioma monoclonal antibody 8H9.
    Luther N; Cheung NK; Dunkel IJ; Fraser JF; Edgar MA; Gutin PH; Souweidane MM
    Neurosurgery; 2008 Dec; 63(6):1166-74; discussion 1174. PubMed ID: 19057330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.
    Lassman AB; Rossi MR; Raizer JJ; Abrey LE; Lieberman FS; Grefe CN; Lamborn K; Pao W; Shih AH; Kuhn JG; Wilson R; Nowak NJ; Cowell JK; DeAngelis LM; Wen P; Gilbert MR; Chang S; Yung WA; Prados M; Holland EC
    Clin Cancer Res; 2005 Nov; 11(21):7841-50. PubMed ID: 16278407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug combinations enhancing the antineoplastic effects of erlotinib in high-grade glioma.
    Karpel-Massler G; Wirtz CR; Halatsch ME
    Recent Pat Anticancer Drug Discov; 2011 Sep; 6(3):384-94. PubMed ID: 21612575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG).
    Yalon M; Rood B; MacDonald TJ; McCowage G; Kane R; Constantini S; Packer RJ
    Pediatr Blood Cancer; 2013 Jan; 60(1):71-6. PubMed ID: 22434731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors.
    Yamamoto N; Horiike A; Fujisaka Y; Murakami H; Shimoyama T; Yamada Y; Tamura T
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):489-96. PubMed ID: 17483950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer.
    Lind JS; Lagerwaard FJ; Smit EF; Senan S
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1391-6. PubMed ID: 19289264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patients.
    Hata A; Katakami N; Kunimasa K; Yoshioka H; Fujita S; Kaji R; Tachikawa R; Tomii K; Imai Y; Iwasaku M; Ishida T
    Jpn J Clin Oncol; 2011 Dec; 41(12):1366-72. PubMed ID: 22058419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment schedule is of importance when gefitinib is combined with irradiation of glioma and endothelial cells in vitro.
    Andersson U; Johansson D; Behnam-Motlagh P; Johansson M; Malmer B
    Acta Oncol; 2007; 46(7):951-60. PubMed ID: 17917826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
    Smith J
    Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraarterial therapy of human glioma xenografts in athymic rats using 4-hydroperoxycyclophosphamide.
    Schuster JM; Friedman HS; Archer GE; Fuchs HE; McLendon RE; Colvin OM; Bigner DD
    Cancer Res; 1993 May; 53(10 Suppl):2338-43. PubMed ID: 8485721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B; Chang CM; Yuan M; McKenna WG; Shu HK
    Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor status and the response of bladder carcinoma cells to erlotinib.
    Jacobs MA; Wotkowicz C; Baumgart ED; Neto BS; Rieger-Christ KM; Bernier T; Cohen MS; Libertino JA; Summerhayes IC
    J Urol; 2007 Oct; 178(4 Pt 1):1510-4. PubMed ID: 17707060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours.
    Halatsch ME; Schmidt U; Behnke-Mursch J; Unterberg A; Wirtz CR
    Cancer Treat Rev; 2006 Apr; 32(2):74-89. PubMed ID: 16488082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand?
    Karpel-Massler G; Schmidt U; Unterberg A; Halatsch ME
    Mol Cancer Res; 2009 Jul; 7(7):1000-12. PubMed ID: 19584260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor necrosis factor-alpha enhances antitumor effects of radiation against glioma xenografts.
    Gridley DS; Archambeau JO; Andres MA; Mao XW; Wright K; Slater JM
    Oncol Res; 1997; 9(5):217-27. PubMed ID: 9306429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines.
    Bax DA; Gaspar N; Little SE; Marshall L; Perryman L; Regairaz M; Viana-Pereira M; Vuononvirta R; Sharp SY; Reis-Filho JS; Stávale JN; Al-Sarraj S; Reis RM; Vassal G; Pearson AD; Hargrave D; Ellison DW; Workman P; Jones C
    Clin Cancer Res; 2009 Sep; 15(18):5753-61. PubMed ID: 19737945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers.
    Petty WJ; Dragnev KH; Memoli VA; Ma Y; Desai NB; Biddle A; Davis TH; Nugent WC; Memoli N; Hamilton M; Iwata KK; Rigas JR; Dmitrovsky E
    Clin Cancer Res; 2004 Nov; 10(22):7547-54. PubMed ID: 15569985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interstitial continuous infusion therapy in a malignant glioma model in rats.
    Tange Y; Kondo A; Egorin MJ; Mania-Farnell B; Daneriallis GM; Nakazaki H; Sredni ST; Rajaram V; Goldman S; Soares MB; Tomita T
    Childs Nerv Syst; 2009 Jun; 25(6):655-62. PubMed ID: 19212774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
    Wiedmann M; Feisthammel J; Blüthner T; Tannapfel A; Kamenz T; Kluge A; Mössner J; Caca K
    Anticancer Drugs; 2006 Aug; 17(7):783-95. PubMed ID: 16926628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.